HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestrant in a novel first-line switch setting in HR-positive, HER2-negative metastatic breast cancer, dealing an early blow to the British pharma's $5 billion peak sales plan.

By FierceBiotech · May 2, 2026 · via FierceBiotech
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
PipelineBriefing
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
FDA authorizes Auvelity for agitation tied to Alzheimer’s disease, positioning Axsome’s NMDA/sigma-1 modulator…
May 2, 2026
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
PipelineBioPharma Dive ↗
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still…
May 1, 2026
FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
PipelineFiercePharma ↗
FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and…
May 1, 2026